Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study.

Sci Rep · 2017 · PMC5638859 · PMID 29026148

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

of borderline significanceno p-value reported

At multivariable analysis adjusted for other potential confounding factors, statin use (OR, 0.51; 95% CI, 0.32–0.80) was associated to a reduced risk of PDAC occurrence, while the association for aspirin use was of borderline significance (OR, 0.64; 95% CI, 0.40–1.01).

also in 2,624 other papers

borderline significantno p-value reported

Overall use of aspirin and statins and risk of pancreatic cancer Seventy-eight cases (19.1%) and 191 controls (23.4%) reported ever use of aspirin, which was associated with a statistically borderline significant reduced PDAC risk (age- and sex-adjusted OR, 0.74; 95% CI, 0.54–1.02; Table 2 ).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.